The Institute for Clinical and Economic Review (ICER) in a new report suggests a roughly 25 percent discount on AbbVie’s upadacitinib, which costs $59,860 per year.
ICER reviewed the following drugs used to treat rheumatoid arthritis:
- AbbVie’s upadacitinib (Rinvoq);
- Pfizer’s tofacitinib (Xeljanz); and
- Eli Lilly’s baricitinib (Olumiant).
To read the report, click here.